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ABSTRACT 
Background: Fatalistic beliefs may be implicated in longer help-seeking intervals, and 
consequently, greater risk of advanced stage at cancer diagnosis.  
Methods: We examined associations between fatalism and stage at diagnosis in a population-
based cohort of 4,319 U.S. patients with newly-diagnosed lung or colorectal cancer participating 
in the Cancer Care Outcomes and Research Surveillance (CanCORS) study. Fatalistic beliefs 
were assessed with an established measure. A fatalism score (range 4-16) was created by 
summing Likert-scale responses to four items. Cancer stage at diagnosis was abstracted from 
medical records by trained staff. Logistic regression was used to assess the association 
between fatalism score and advanced stage at diagnosis (IV vs I-III), adjusting for socio-
demographic and clinical characteristics.  
Results: Overall, 917 (21%) patients had stage IV cancers (lung: 28%, colorectal: 16%). The 
mean fatalism score was 10.7 (median=11, inter-quartile range 9-12). In adjusted analyses, a 
higher fatalism score was associated with greater odds of stage IV diagnosis (odds ratio per unit 
increase in fatalism=1.05, 95% confidence interval 1.02-1.08, p=0.003). Patients with the 
highest fatalism score had an adjusted 8.9% higher frequency of stage IV diagnosis compared 
with patients with the lowest score (25.4% vs. 16.5%).  
Conclusions: In this large and socioeconomically, geographically and ethnically diverse 
population of patients with lung and colorectal cancer, fatalistic beliefs were associated with 
higher risk of advanced stage at diagnosis. Longitudinal studies are needed to confirm 
causation. 
Impact: These findings support the value of incorporating information about the curability of 
early-stage cancers in public education campaigns. 
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INTRODUCTION 
Many cancer patients are diagnosed after a symptomatic presentation, because effective 
screening tests exist for few cancer sites and participation rates are sub-optimal. For example, 
in England, more than 90% of all cancer patients are diagnosed following symptomatic 
presentations (1). As stage at diagnosis is a key determinant of cancer survival, interventions to 
ensure that symptomatic patients are diagnosed at the earliest possible stage can help to 
reduce cancer mortality.  
Psychosocial factors are important candidates for influencing the length of the period from 
symptom onset to presentation to a doctor (i.e. the ‘patient interval’), and, consequently, the 
stage at diagnosis (2,3). These factors encompass both cognitive (e.g. awareness of potential 
associations of symptoms with cancer) and emotional processes (e.g. fear of cancer or 
embarrassment about symptoms) (4).  
Fatalism, whether it relates to a general belief that life events are pre-determined and inevitable, 
or ‘cancer fatalism’, defined by Powe as ‘the belief that death is inevitable when cancer is 
present’ (5), has been implicated in longer patient intervals in a study of intended help-seeking 
for breast cancer among asymptomatic women (6). Individuals with more fatalistic beliefs may 
be both more fearful of a cancer diagnosis and more sceptical about the value of early detection 
of cancer, and therefore, may delay seeking medical help (7). Several studies have shown that 
cancer fatalism influences cancer screening uptake (8-10). Direct evidence that fatalism is 
associated with longer patient intervals in symptomatic patients is limited, although two small 
single-centre studies including a few hundred patients each and primarily examining the 
potential determinants of ethnic disparities in cancer outcomes have shown that fatalistic beliefs 
were associated with advanced stage of diagnosis of breast and lung cancer (11,12). 
Specifically, an association between endorsing the fatalistic belief ‘if it’s meant to be, I will stay 
healthy’ and advanced stage at diagnosis was reported in a sample of 540 women with breast 
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cancer (11). Further, in 357 patients with lung cancer; there was an independent association 
between one of three fatalism items (‘bad things are meant to be’) and advanced stage at 
diagnosis (12). It is therefore important to extend the focus of prior inquiries about the potential 
influence of fatalism on stage at diagnosis to larger and more representative samples of patients 
and encompass cancers other than those previously studied.  
Against this background, we hypothesised that cancer patients with higher scores on measures 
of fatalistic beliefs will be more likely to be diagnosed with cancer at a more advanced stage. 
We have subsequently examined this hypothesis association in a large population-based survey 
of newly-diagnosed patients with lung and colorectal cancer.  
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MATERIALS AND METHODS 
Data  
Study design and participants: The CanCORS (Cancer Care Outcomes Research and 
Surveillance) study prospectively enrolled U.S. adults diagnosed with lung or colorectal cancer 
in 2003-2005 who lived in certain geographic areas (northern California; Los Angeles County, 
California; North Carolina; Iowa; or Alabama) or received care in one of five health maintenance 
organizations (HMOs) or fifteen Veterans Affairs medical centers (13,14). Participants were 
representative of U.S. patients with these cancers (15). Patients were identified within weeks of 
diagnosis and interviews (with the patient or a surrogate –if the patient was deceased or too ill 
to participate) conducted approximately 4-6 months after diagnosis. Interviews were conducted 
by telephone; trained interviewers used computer-assisted telephone interviewing software to 
navigate complex skip patterns. The study was approved by human subjects committees at all 
participating institutions. 
Among 9,732 CanCORS participants, we studied the 5,453 for whom interviews were 
conducted with the patients themselves. We then excluded 761 patients who did not respond to 
all four fatalism items and 373 patients for whom data on stage at diagnosis were not available, 
resulting in an analysis sample of 4,319 patients (Figure 1). 
Data items: A four-item measure assessing general fatalism that had been developed for the 
Americans’ Changing Lives Panel Study (House JS, 
http://sodapop.pop.psu.edu/codebooks/hwboa/acl.pdf) and reported by Jacobson was included 
in the questionnaire for patients who completed the survey themselves (16). Patients were 
asked how strongly they agreed or disagreed with the following four statements:  
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 When bad things happen, we are not supposed to know why, we are just supposed to 
accept them. 
 People die when it is their time to die and nothing can change that. 
 Everything that happens is a part of God’s plan. 
 If bad things happen, it is because they were meant to be. 
Responses were on a 4-point Likert scale (strongly agree/agree/disagree/strongly disagree; 
coded as 4, 3, 2, and 1). Jacobson reported results of a factor analysis showing that the four 
items formed a single scale with high internal reliability (Alpha=0.77) (16), whereas in our 
analysis sample we have observed a slightly higher value (Alpha=0.79). 
Trained abstractors documented stage at diagnosis from medical records based on the criteria 
of the American Joint Committee on Cancer, 6th edition. Medical records were available for 
87% of patients; for other patients, stage data were obtained from cancer registries. Information 
was also available on cancer site (colorectal or lung), age, sex, race/ethnicity, education, 
income, marital status, smoking status, count of self-reported co-morbid conditions using the 
Katz et al. questionnaire (17), self-reported health status a year before the interview (0-100 on a 
visual analogue scale, 100=perfect health), symptom status at diagnosis (yes/no), and 
CanCORS study site. Variables were categorized as in Table 1. 
Statistical analysis 
We compared patients included in the analysis with those excluded (because of not completing 
an interview themselves, missing responses to all four fatalism items or missing stage at 
diagnosis, see Figure 1) using logistic regression. After examining Spearman’s rank correlation 
coefficients for pair-wise associations between the four fatalism items, to maximize power, 
replies to each of the four items were summed and the total score was used in the main 
analysis; higher scores reflected higher levels of fatalistic beliefs. We categorized advanced 
stage at diagnosis as stage IV (vs. I-III) and examined crude and adjusted associations between 
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advanced stage at diagnosis and fatalism using logistic regression. We initially tested whether 
there was evidence that the association between fatalism and stage at diagnosis varied by 
cancer site by an interaction term fatalism*cancer site, but found no such evidence (p=0.40). 
We therefore included all patients in the same model, adjusting for cancer site, and sex, age, 
race/ethnicity, education, income, marital status, smoking status, number of co-morbidities, 
health status a year before interview, and study site. Subsequently, to aid interpretation, we 
predicted the proportion of patients diagnosed in stage IV for each score of the fatalism scale, 
by direct standardisation using the regression model (18). The fully observed dataset was used 
for sample descriptions (Table 1) and 5 imputed datasets, produced through multiple imputation 
as previously described (19), were used in the logistic regression models, and outputs were 
combined with the SAS MIANALYZE procedure. In the present analysis imputed data only 
relate to the small proportion of records with missing income (8%) and education, marital and 
smoking status information (<1% for all three), as all other variables were complete in the 
analysis sample (a priori restricted to patients with fully observed fatalism and stage at 
diagnosis, Text Box). 
Sensitivity and supplementary analyses: In sensitivity analyses we examined alternative 
parameterizations of stage at diagnosis and fatalism score, i.e. by categorising advanced stage 
at diagnosis as stage III/IV vs. I/II; by analysing scores for each fatalism item individually; and by 
excluding the religious beliefs (‘God’s plan’) item from the total fatalism score. In supplementary 
analysis we also examined the potential moderating effect of symptom status at diagnosis by 
repeating the main analysis model, also adjusting for symptom presence at the time of 
diagnosis (yes/no) and an interaction between symptom presence and fatalism score. Lastly, in 
a subgroup of patients with known grade and/or lung cancer tumour type (non-small cell / small 
cell) we have additionally adjusted for tumour grade and/or type. 
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RESULTS 
Sample description. Compared with the final sample (Figure 1), excluded patients (who were 
predominantly deceased, or too ill to participate at the time of the baseline survey and thus were 
not asked the fatalism items) were more likely to have had lung than colorectal cancer and to be 
male, older, Asian and smokers, and with lower educational attainment and income, higher 
count of comorbidities and more advanced stage at diagnosis (p<0.01 for all, Supplementary 
Table 1). Among patients included in the analysis the median age was 65 (inter-quartile range: 
56-73) and there was a slight preponderance of colorectal cancer and male patients (56% and 
55% of the sample, respectively). Just under three quarters of patients where White (72%) and 
7%, 13% and 5% were Hispanic, Black and Asian, respectively. Most patients (82%) had 
symptoms at the time of diagnosis. Further sample details are provided in Table 1.  
Stage at diagnosis. Among all patients 1,266 (29%), 849 (20%), 1287 (30%), and 917 (21%) 
patients were diagnosed in stages I to IV, respectively. The proportion diagnosed with stage IV 
cancers was greater among patients with lung than colorectal cancer (28% vs 16%, p<0.001). 
Fatalism. The mean fatalism score was 10.7 (median score: 11, inter-quartile range: 9-12). 
Responses to the four individual items were moderately correlated (pair-wise Spearman rank 
correlation coefficients range: 0.34 to 0.55, p<0.001 for all). There were differences in fatalism 
scores by race/ethnicity, with mean scores of 10.5 for White, and 11.3, 11.3 and 10.9 for 
Hispanic, Black and Asian patients, respectively (p<0.001). On average, women had higher 
mean fatalism scores than men (10.9 vs 10.5, p<0.001) and the same was true for current 
smokers compared with former smokers and non-smokers (11.0, 10.6, 10.8 respectively, 
p<0.001). Patients with lower educational attainment had higher fatalism scores than patients 
with higher education (11.8, 10.9 and 9.5 respectively for non-high school graduates, high 
school graduates and college graduates, p<0.001). Patients with lower income also had higher 
fatalism scores than patients with higher income (11.3 and 9.8 respectively for patients with 
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annual income <$20,000 and >60,000, p<0.001). There were no notable associations of 
fatalism with count of comorbid conditions, symptomatic detection status, or cancer site. 
Crude associations. In crude analysis (logistic regression), higher fatalism scores were 
associated with advanced stage at diagnosis (odds ratio per unit increase in fatalism=1.05, 95% 
confidence interval (CI): 1.02-1.08, p=0.001). Other factors associated with stage IV diagnosis 
included lung cancer, younger age, lower count of co-morbidities, being a current smoker, and 
symptomatic detection (p<0.01 for all, Table 2).  
Adjusted associations. Adjusted analysis (logistic regression) revealed a very similar association 
between fatalism and stage IV diagnosis (odds ratio per unit increase in fatalism=1.05, 95% CI: 
1.02-1.08, p=0.003, Table 2). Patients with the highest fatalism score (16) had an odds ratio of 
1.77 (95% CI 1.21-2.57) for advanced stage at diagnosis compared with those with the lowest 
score (4) – equivalent to an absolute adjusted difference of 8.9% in the proportion of patients 
diagnosed with stage IV cancers (Table 3). Similarly, patients with the highest score (16) had an 
odds ratio of 1.34 (95% CI 1.10-1.60) for stage IV diagnosis compared with those in mid-scale 
(10) – equivalent to 4.7% increase in the proportion of patients diagnosed with stage IV cancers. 
There was also evidence that lung cancer, male sex, younger age, and lower count of co-
morbid conditions were associated with higher odds of stage IV diagnosis (p<0.01 for all, Table 
2).    
Sensitivity analysis. When we examined the association of fatalism with stage III/IV diagnosis, 
the direction of association remained but its strength was attenuated, such that there was only 
weak evidence for an association (OR=1.03, 95% CI: 1.00-1.05, p=0.055, Supplementary Table 
2). When running logistic regression models that included each individual fatalism item 
separately instead of the total score (four separate models) the observed findings were 
concordant with those of the main analysis, with respective odds ratio >1.0 and some significant 
associations. Repeating the analysis using a total score but excluding the ‘God’s plan’ individual 
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item also produced concordant results (OR=1.06, 95% CI: 1.02 to 1.10, p=0.004). Similarly, 
inclusion of symptomatic detection status and an interaction variable symptomatic 
detection*fatalism score produced concordant findings to those observed in the main analysis 
with no evidence for an interaction (p=0.68). Adjustment for tumour grade and/or lung cancer 
type made no material difference to the findings of the main analysis model. 
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DISCUSSION 
In a large population based survey of patients with lung and colorectal cancer, we observed 
an independent association between higher fatalism scores and advanced stage at 
diagnosis of lung and colorectal cancer. Sensitivity analyses provided concordant findings.  
Although previous research has documented associations between fatalism and lower 
participation in cancer screening (8-10), evidence linking fatalism with clinical outcomes such 
as stage at diagnosis is limited. Our inquiry is methodologically similar to two previous 
studies, and a smaller qualitative study of breast cancer patients (11,12,20), but has a 
substantially larger and socio-demographically and geographically more diverse sample that 
includes patients with both lung and colorectal cancer. 
Powe and Finnie suggest that the two factors that shape fatalism are angst, defined as the 
perceived collapse of meaning in the presence of despair about the future, and nihilism, 
defined as the lived experiences of coping with feelings of meaningless, hopelessness, and 
despair (5). Accordingly, cancer fatalism takes shape as individuals experience others being 
diagnosed with cancer at an advanced stage, leading to poor outcomes and death. This can 
lead to scepticism about the value of cancer screening or prompt symptomatic presentation, 
leading to prolonged intervals to presentation and increasing the risk of advanced stage at 
diagnosis (21). In addition, cultural or religious values emphasising acceptance may 
accentuate fatalistic attitudes among some groups (22). Modifying entrenched fatalistic 
beliefs is not likely to be easy, but evidence that an understanding of the value of prevention 
or early diagnosis can be held in parallel with fatalism suggests that exposure to culturally 
appropriate information on the value of early detection might be beneficial (23). If fatalistic 
beliefs can be modified, campaigns to promote symptom awareness are also likely to 
contribute to more rapid symptomatic presentation (24). In a recent development of a new 
scale, Shen et al.  propose that fatalism is a multidimensional construct, encompassing 
‘predestination’, ‘luck’ and ‘pessimism’ (25). The Fatalism scale used in the present study 
more closely resembles the predestination dimension, and it will be important in future work 
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to examine the differential effects of these three elements on screening and help-seeking 
behaviours.  
Strengths of our study include its relatively large and diverse patient population and high 
data quality, including information on stage at diagnosis abstracted from medical records 
and the use of validated instruments for assessing fatalism. We were also able to adjust our 
analysis for a large number of potential confounders, including age, sex, race/ethnicity, 
education, income, co-morbidity, smoking status and prior health status. 
Our study has two principal limitations. First, our analysis included only patients who were 
alive and able to complete the baseline survey, resulting in relative under-representation of 
older and more co-morbid patients and those with more advanced stage at diagnosis 
(Supplementary Table 1). However, sample attrition and non-response patterns are a 
necessary but not sufficient condition for non-response bias in estimates of associations. 
After appropriate adjustment for case-mix the effect of such bias in surveys with an 
appropriately defined sampling frame is small (26,27). Achieving more representative patient 
samples might be possible if interviews are conducted sooner after diagnosis; however, this 
is rarely feasible in large population-based studies of cancer patients.  
Second, as for any cross-sectional study, the causal direction of the observed association 
cannot be proven. Fatalism could lead to advanced stage at diagnosis, but it is also possible 
that advanced stage at diagnosis could lead to higher fatalism scores, although Powe has 
reported unpublished data indicating that cancer fatalism has declined from pre- to post-
diagnosis (28). Nevertheless, a causal association of fatalism with advanced stage at 
diagnosis is plausible. If people believe that cancer is inevitably fatal, then they might delay 
or avoid seeking medical help after symptom onset or participation in cancer screening, and 
thus have a higher risk of advanced cancer at diagnosis. Although we did not observe 
statistically significant differences in fatalism scores based on presence or absence of 
symptoms, patients may have differed in how long they waited to seek care after developing 
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symptoms. Other studies of asymptomatic individuals have documented associations 
between fatalism and both intended help-seeking and participation in cancer screening, 
further supporting a causal effect of fatalism on the length of the patient interval and stage at 
diagnosis (6-10). Prospective cohort studies involving fatalism measurement in individuals 
who are free of cancer at study entry would be ideal, but would require large populations and 
adequate follow-up to achieve sufficient numbers of cancer cases. Critically, new 
prospective studies would be associated with ethical challenges (i.e. leaving fatalistic beliefs 
about cancer curability unchallenged during follow-up could be considered unethical). This 
may explain why the few previous studies have also measured fatalism after diagnosis 
(11,12).  
When fatalism items form part of surveys of patients after a cancer diagnosis, there may be 
ethical concerns about use of cancer-specific fatalism items, and this was the rationale for 
using a general fatalism item in the CanCORS study. A qualitative study confirmed low 
acceptability of cancer fatalism questions among recently diagnosed breast cancer patients 
(29). General (as opposed to cancer-specific) fatalism items may have both merits (e.g. less 
likely to be prone to bias resulting from knowledge of cancer diagnosis) and limitations (it 
makes the argument for public health interventions aimed at reducing ‘cancer fatalism’ less 
direct). Subject to research ethics considerations, future surveys of cancer patients may be 
able to investigate differences in results from use of general and cancer-specific fatalism 
items. 
In conclusion, we identified an association between fatalism and advanced stage at 
diagnosis for patients with newly-diagnosed lung and colorectal cancer, most of whom had 
presented with symptoms. The consistency of these findings with those from other 
qualitative and quantitative studies, the plausibility of the association and its large size 
suggest that the findings should be considered in the context of public health policy 
initiatives and education campaigns designed to shorten the patient interval of newly 
diagnosed cancer cases (30,31). Traditionally such strategies have focused on cognitive 
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aspects (i.e. ‘awareness’ of cancer symptoms) but including ‘anti-fatalism’ components could 
have a powerful impact. Such approaches may include factual information about the high 
probability of long-term survival when the diagnosis occurs at a non-advanced stage and the 
availability of effective treatments that offer good health-related quality of life. 
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Table 1. Distribution of the fatalism scores (n=4,319 patients who completed a post-diagnosis 
interview themselves, with fully observed information on fatalism score and stage at 
diagnosis) 
 Patient characteristic N Median Mean P 
Sex* Men 2372 11 10.5 <0.001 
 Women 1947 11 10.9  
Age at diagnosis* <55 950 11 10.8 <0.001 
55-59 553 10 10.4  
 60-64 604 11 10.4  
 65-69 671 11 10.7  
 70-74 588 11 10.7  
 75-80 525 11 10.9  
 80+  428 11 10.9  
Race/ethnicity White 3115 11 10.5 <0.001 
Hispanic 310 12 11.3  
 Black 577 11 11.3  
 Asian 200 11 10.9  
 Other 117 11 11.3  
Educational attainment <High school 730 12 11.8 <0.001 
 High school/some college 2514 11 10.9  
 ≥College degree 1070 9 9.5  
 Missing 5 12 12.4  
Income in past year   
(US $) 
<20,000 1181 12 11.3 <0.001 
20,000 - 39,999 1133 11 10.8  
 40,000 - 59,999 677 10 10.4  
 ≥60,000 1000 10 9.8  
 Missing 328 12 11.2  
Study site 5 Integrated health-care delivery systems 
systemsrch Network (CRN) 
606 10 10.3 <0.001 
8 counties in Northern California  905 11 10.4  
 Los Angeles County 962 11 10.5  
 State of Alabama 486 12 11.4  
 22 counties in North Carolina 446 11 11.1  
 State of Iowa 409 11 11.0  
 15 Veterans Affairs Medical Centers 505 11 10.9  
Married/living with 
partner 
Yes 2686 11 10.6 0.01 
No 1630 11 10.8  
 Missing 3 9 9.7  
Smoking status Never smoker 1242 11 10.8 <0.001 
Former smoker 2583 11 10.6  
 Current smoker 487 11 11.0  
 Missing 7 11 11.1  
Co-morbidities         
(count of) 
0** 1724 11 10.7 0.24 
1 1441 11 10.6  
 2 718 11 10.8  
 ≥3 436 11 10.9  
Symptom status at 
diagnosis 
‘Yes, symptomatic’ 3541 11 10.7 0.23 
‘No, diagnosed without symptoms’ 777 11 10.6  
 Missing 1 12 12.0  
Cancer site * Colorectal 2396 11 10.6 0.06 
Lung 1923 11 10.8  
Stage at diagnosis * I 1266 11 10.7 0.007 
II 849 11 10.5  
 III 1287 11 10.6  
 IV 917 11 10.9  
Fatalism scores * 4 98    
5 47    
 6 108    
 7 151    
 8 443    
 9 505    
 10 544    
 11 664    
 12 923    
 13 322    
 14 179    
 15 133    
 16 202    
Health status a year 
before interview 
Median 90 (inter-quartile range 75-100) 4,286    
Total  4,319    
* Information on these variables was fully observed (no ‘missing’ values) in the analysis sample 
**Included missing observations 
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Table 2: Factors associated with diagnosis of cancer at stage IV* 
Variable  
Stage 
IV 
(%) 
Crude 
odds 
ratios 
for stage 
IV 
95% 
confidence 
intervals 
p* 
Adjusted 
odds 
ratios 
for stage 
IV 
95% 
confidence 
intervals 
p* 
Fatalism (per 
one unit 
increase 4-16 
scale) 
  1.05 1.02-1.08 0.001 1.05 1.02-1.08 0.003 
Sex Men 22.6 -  0.015 
-  
<0.001 
Women 19.6 0.83 0.72-0.97 0.73 0.61-0.86 
Age at 
diagnosis 
<55 24.6 -  
<0.001 
-  
<0.001 
55-59 24.1 0.97 0.76-1.24 0.93 0.72-1.20 
60-64 23.7 0.95 0.75-1.21 0.88 0.69-1.14 
65-69 20.0 0.76 0.60-0.97 0.72 0.56-0.93 
70-74 21.8 0.85 0.67-1.09 0.83 0.63-1.08 
75-80 16.8 0.62 0.47-0.81 0.60 0.44-0.80 
80 or more 13.3 0.47 0.34-0.64 0.48 0.34-0.67 
Race/ethnicity 
White 20.3 -  
0.204 
-  
0.87 
Hispanic 23.6 1.20 0.91-1.59 1.18 0.86-1.62 
Black 23.5 1.20 0.97-1.48 1.03 0.82-1.30 
Asian 24.5 1.27 0.91-1.78 1.11 0.77-1.60 
Other 23.9 1.24 0.80-1.91 1.09 0.70-1.72 
Education 
<High school 20.4 -  
0.019 
-  
0.099 
High school/some 
college 
22.6 1.14 0.93-1.40 1.23 0.98-1.53 
≥College degree 18.5 0.89 0.70-1.13 1.06 0.80-1.41 
Income (US $) 
<20,000 23.0 -  
0.50 
-  
0.82 
20,000 - 39,999 21.9 0.92 0.75-1.12 0.97 0.78-1.20 
40,000 - 59,999 20.4 0.86 0.69-1.08 0.89 0.68-1.15 
≥60,000 20.3 0.88 0.71-1.07 0.91 0.70-1.19 
Study site 
5 Integrated health-
care delivery 
systems  
20.1 -  
0.001 
-  
0.134 
8 counties in 
Northern California  
23.1 1.19 0.93-1.53 1.20 0.93-1.56 
Los Angeles 
County 
20.6 1.03 0.80-1.32 0.97 0.74-1.26 
State of Alabama 23.3 1.20 0.90-1.61 1.11 0.82-1.51 
22 counties in 
North Carolina 
13.5 0.62 0.44-0.86 0.85 0.59-1.21 
State of Iowa 23.2 1.20 0.89-1.63 0.82 0.59-1.13 
15 Veterans Affairs 
Medical Centers 
23.8 1.24 0.93-1.65 1.00 0.73-1.37 
Married/living 
with partner 
Yes 20.7 -  0.28 -  0.134 
No 22.1 1.09 0.94-1.26 1.13 0.95-1.34 
Smoking status 
Never smoker 18.8 -  
<0.001 
-  
0.109 Ex-smoker 21.2 1.16 0.98-1.37 0.89 0.73-1.09 
Current smoker 27.5 1.63 1.28-2.09 1.13 0.85-1.49 
Co-morbidities 
0 23.9 -  
0.004 
-  
0.003 
1 20.2 0.81 0.68-0.97 0.78 0.65-0.94 
2 18.8 0.74 0.59-0.92 0.70 0.56-0.89 
≥3 17.9 0.69 0.53-0.90 0.65 0.48-0.87 
Cancer site Lung 27.6 -  <0.001 
-  
<0.001 
Colorectal 16.2 0.51 0.44-0.59 0.44 0.36-0.52 
Symptoms at 
diagnosis 
Yes 23.4 2.33 1.85-2.94 
<0.001 
   
No 11.6 -     
Health status a 
year before 
interview (0-
100) 
  
1.00 1.00-1.01 0.028 1.00 1.00-1.01 0.223 
*From univariable or multivariable regression, as applicable. Multivariable regression models adjusted 
for all variables in the table except symptom status at diagnosis. 
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Table 3. Proportion of patients diagnosed with stage IV cancers (crude and case-mix adjusted) 
Fatalism 
score 
n Observed 
(crude) rate 
Adjusted 
percentage* 
4 98 18.4% 16.5% 
5 47 14.9% 17.2% 
6 108 18.5% 17.8% 
7 151 17.9% 18.5% 
8 443 16.7% 19.2% 
9 505 21.4% 19.9% 
10 544 23.7% 20.7% 
11 664 21.8% 21.4% 
12 923 19.2% 22.2% 
13 322 27.0% 23.0% 
14 179 16.2% 23.8% 
15 133 27.8% 24.6% 
16 202 29.2% 25.4% 
 
*Adjusted proportions calculated from the logistic regression model – this is the expected percentage 
that would have been observed if the case-mix of patients in each fatalism score category was the 
same as in the total sample 
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Figure legend 
Figure 1. Analysis sample derivation 
 
